Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.82 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Acetate SCHEMBL28080806 | 0.95 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10SOAT1TSHR | |
| Ethyl Acetate SCHEMBL1330811 | 0.91 | — | — | |
| Ethyl Acetate SCHEMBL1331901 | 0.91 | — | — | |
| Ethyl Acetate SCHEMBL28457765 | 0.91 | ALDH1A1 (1.00) | ALDH1A1LMNAHSD17B10SOAT1TSHR | |
| Ethyl Acetate SCHEMBL70316 | 0.91 | ALDH1A1 (1.00) | ALDH1A1LMNAHSD17B10SOAT1TSHR | |
| Ethyl Acetate SCHEMBL28615209 | 0.91 | ALDH1A1 (1.00) | ALDH1A1LMNAHSD17B10SOAT1TSHR | |
| Ethyl Acetate SCHEMBL30152067 | 0.91 | — | — | |
| Ethyl Acetate SCHEMBL1331990 | 0.91 | — | — | |
| Ethyl Acetate SCHEMBL8506185 | 0.91 | ALDH1A1 (1.00) | ALDH1A1LMNAHSD17B10SOAT1TSHR | |
| Ethyl Acetate SCHEMBL155 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11142535-B2 | Heterocyclic compound as Syk inhibitor and/or Syk-HDAC dual inhibitor | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2021-10-12 | — | — | US | disclosed |
| US-20200079795-A1 | HETEROCYCLIC COMPOUND AS SYK INHIBITOR AND/OR SYK-HDAC DUAL INHIBITOR | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2020-03-12 | — | — | US | disclosed |
| CN-108024996-A | BRUTON'S TYROSINE KINASE INHIBITOR COMBINATIONS AND USES THEREOF | 药品循环有限责任公司 | 2018-05-11 | — | — | CN | disclosed |
| US-8404681-B2 | Xanthones, thioxanthones and acridinones as DNA-PK inhibitors | LUITPOLD PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| CN-1942182-B | dipeptidyl peptidase IV inhibitor for regulating glucose metabolism | TUFTS COLLEGE | 2010-05-26 | — | — | CN | disclosed |
| US-20070167441-A1 | Xanthones, thioxanthones and acridinones as dna-pk inhibitors | LUITPOLD PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| CN-1942182-A | Dipeptidyl peptidase IV inhibitor for regulating glucose metabolism | TUFTS COLLEGE (US) | 2007-04-04 | — | — | CN | disclosed |
| EP-1660473-A2 | XANTHONES, THIOXANTHONES AND ACRIDINONES AS DNA-PK INHIBITORS | Luitpold Pharmaceuticals, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2004085418-A2 | XANTHONES, THIOXANTHONES AND ACRIDINONES AS DNA-PK INHIBITORS | LUITPOLD PHARMACEUTICALS, INC. (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167441-A1 | Xanthones, thioxanthones and acridinones as dna-pk inhibitors | DCK, DTYMK, XPA | ALDH1A1 3664/4885LMNA 746/4885HSD17B10 2442/4885 |
| US-11142535-B2 | Heterocyclic compound as Syk inhibitor and/or Syk-HDAC dual inhibitor | SYK, HDAC1, HDAC2 | ALDH1A1 2514/4885LMNA 4459/4885HSD17B10 1385/4885 |
| US-20200079795-A1 | HETEROCYCLIC COMPOUND AS SYK INHIBITOR AND/OR SYK-HDAC DUAL INHIBITOR | SYK, HDAC1, HDAC2 | ALDH1A1 2514/4885LMNA 4459/4885HSD17B10 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.